SEC Filing Summary: Synaptogenix, Inc. (SNPX)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synaptogenix, Inc. on June 21, 2024, covering events occurring on June 20, 2024. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York. The filing primarily addresses executive compensation arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and employment agreements rather than financial performance data.
Material Changes
The material change reported is the execution of Amendment No. 3 to the Offer Letter with Alan J. Tuchman, M.D., the Company's Chief Executive Officer. Key details include:
- Effective Date: June 7, 2024.
- Execution Date: June 20, 2024.
- Term Extension: Dr. Tuchman's employment term was extended through December 7, 2024.
- Renewal Provision: The agreement includes automatic monthly renewals thereafter unless terminated earlier in accordance with the Offer Letter terms.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors. The document notes that the description of the Amendment is qualified in its entirety by reference to the full text of the agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 (Third Amendment to Offer Letter) for specific compensation details and termination clauses not summarized in the text.
- Verify the status of the automatic monthly renewal provision and any conditions for termination.
- Confirm the alignment of this employment extension with the company's current strategic and financial position, as no financial metrics are provided in this filing.